Guardant Health heads into its July 30 earnings print with a fresh wave of analyst target increases, a stock up 30% over the past month, and options traders growing noticeably more cautious about what comes next.
The analyst story is unusually concentrated this week. Citigroup raised its target to $215 from $150 this morning, maintaining Buy. BofA lifted to $190 from $135 on Monday, also keeping Buy. Evercore ISI moved to $200 from $160 on the same day. That's three bellwether raises in two days, all maintaining positive ratings, all chasing a stock that has already run hard. The consensus mean target is $155.25 — now below the current price of $162.92, which tells you something important: the Street is still catching up to a move that has already happened. The bull case centres on FDA approvals, the Shield colorectal screening ramp, and longer-term global expansion in precision oncology. The bear case hasn't changed: sensitivity limitations on Shield relative to competing tests, high cash burn, and competition in liquid biopsy all remain live concerns. The forward EPS improvement factor ranks in the 99th percentile, and analyst recommendation divergence also ranks at 99 — the data suggests the Street has rarely been this uniformly positive on GH.
Positioning has loosened considerably since the note published a week ago. Short interest is essentially flat on the week at 9.7% of free float — down just 0.8% — but the more telling move is in borrow availability, which has expanded dramatically to roughly 2,449%, more than double the 1,209% reading two weeks prior. That level of availability means there are approximately 24 shares available to borrow for every share currently shorted. Borrowing costs have drifted lower over the month, now running near 0.45%, down from around 0.55% in early June. The ORTEX short score has also eased from 53 in late June to 50.2 today, hovering right at the midpoint — neither a strongly bearish nor bullish reading. Short sellers are not pressing new positions into the rally.
Options tell a different story about near-term risk appetite. The put/call ratio has climbed to 0.87, almost two standard deviations above its 20-day average of 0.75 — a notably defensive posture. The ratio was running well below 0.73 through most of June. The move higher in PCR over the past week, coinciding with the stock's latest leg up from $150 to $163, points to growing demand for downside protection as the price runs toward and through analyst targets. It's worth noting the 52-week PCR high is 1.43, so the current reading is elevated but not extreme — this looks more like pre-earnings hedging than outright fear.
The insider picture has shifted from the prior week's note. The dramatic co-CEO selling by AmirAli Talasaz near $150-$153 that defined the previous piece has been followed by routine company award transactions on July 1, plus smaller sales by the Chief Legal Officer and Chief Commercial Officer totalling roughly $1.2 million. These are largely plan-driven. The 90-day net insider value figure is now a positive $8.8 million — a meaningful swing from the negative $40 million cited last week — suggesting the composition of insider activity has normalised after Talasaz's large-scale disposal. T. Rowe Price added 2.16 million shares through May, and BlackRock added 665,000 through June, providing institutional ballast.
GH is up 8.6% on the week but gave back 3.5% on Tuesday alone — a reminder that momentum at these levels is fragile. Peers were mixed: HQY gained 10.4% on the week while CSTL fell 2%. The Q2 print on July 30 will put the Shield commercial ramp under the microscope, and with analyst targets now clustered well above the current price after the latest wave of raises, the next question is whether revenue execution closes the gap between the Street's ambition and the stock's reality.
See the live data behind this article on ORTEX.
Open GH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
